CN100480255C - A1腺苷受体的部分和完全激动剂 - Google Patents

A1腺苷受体的部分和完全激动剂 Download PDF

Info

Publication number
CN100480255C
CN100480255C CNB038193612A CN03819361A CN100480255C CN 100480255 C CN100480255 C CN 100480255C CN B038193612 A CNB038193612 A CN B038193612A CN 03819361 A CN03819361 A CN 03819361A CN 100480255 C CN100480255 C CN 100480255C
Authority
CN
China
Prior art keywords
purin
formula
compound
dimethyl
diol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038193612A
Other languages
English (en)
Chinese (zh)
Other versions
CN1675235A (zh
Inventor
杰夫·扎布沃茨基
文卡塔·帕勒
埃尔法蒂赫·埃尔扎因
李小芬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Palo Alto Inc
Original Assignee
CV Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CV Therapeutics Inc filed Critical CV Therapeutics Inc
Publication of CN1675235A publication Critical patent/CN1675235A/zh
Application granted granted Critical
Publication of CN100480255C publication Critical patent/CN100480255C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CNB038193612A 2002-08-15 2003-08-15 A1腺苷受体的部分和完全激动剂 Expired - Fee Related CN100480255C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40371202P 2002-08-15 2002-08-15
US60/403,712 2002-08-15
US45009403P 2003-02-25 2003-02-25
US60/450,094 2003-02-25

Publications (2)

Publication Number Publication Date
CN1675235A CN1675235A (zh) 2005-09-28
CN100480255C true CN100480255C (zh) 2009-04-22

Family

ID=31891396

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038193612A Expired - Fee Related CN100480255C (zh) 2002-08-15 2003-08-15 A1腺苷受体的部分和完全激动剂

Country Status (15)

Country Link
US (2) US7022681B2 (https=)
EP (1) EP1537133B1 (https=)
JP (1) JP4596913B2 (https=)
KR (1) KR20050067384A (https=)
CN (1) CN100480255C (https=)
AT (1) ATE368048T1 (https=)
AU (1) AU2003263846B2 (https=)
CA (1) CA2495370A1 (https=)
DE (1) DE60315164T2 (https=)
ES (1) ES2288632T3 (https=)
MX (1) MXPA05001844A (https=)
NO (1) NO20051296L (https=)
NZ (1) NZ538590A (https=)
RU (1) RU2340623C2 (https=)
WO (1) WO2004016635A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2528385C (en) 2003-06-06 2011-03-15 Endacea, Inc. A1 adenosine receptor antogonists
WO2008143667A1 (en) * 2007-05-17 2008-11-27 Cv Therapeutics, Inc. Process for preparing an a2a-adenosine receptor agonist and its polymorphs
JP2014530910A (ja) * 2011-10-24 2014-11-20 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ 新規化合物
JP6584521B2 (ja) * 2015-02-24 2019-10-02 ファイザー・インク 抗がん剤として有用な置換ヌクレオシド誘導体
JP6643719B2 (ja) * 2016-05-31 2020-02-12 セントラル硝子株式会社 ３，３，３−トリフルオロプロパノールの製造方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1501941A (zh) * 2001-03-20 2004-06-02 化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1254888A (en) * 1984-10-26 1989-05-30 Bharat Trivedi N.sup.6-bicycloadenosines
USRE36494E (en) * 1990-02-20 2000-01-11 Discovery Therapeutics, Inc. 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
US5140015A (en) * 1990-02-20 1992-08-18 Whitby Research, Inc. 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
US5278150A (en) * 1992-04-24 1994-01-11 Whitby Research, Inc. 2-hydrazoadenosines and their utility for the treatmeat of vascular conditions
GB9301000D0 (en) * 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
US5589467A (en) * 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
WO1997033591A1 (en) * 1996-03-13 1997-09-18 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
WO1998016539A1 (en) * 1996-10-14 1998-04-23 Novo Nordisk A/S Novel therapeutically active adenosine derivatives
GB9723589D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9813554D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1501941A (zh) * 2001-03-20 2004-06-02 化合物

Also Published As

Publication number Publication date
NZ538590A (en) 2006-10-27
CN1675235A (zh) 2005-09-28
US7022681B2 (en) 2006-04-04
JP2006505525A (ja) 2006-02-16
US20060135467A1 (en) 2006-06-22
EP1537133A2 (en) 2005-06-08
CA2495370A1 (en) 2004-02-26
ES2288632T3 (es) 2008-01-16
RU2340623C2 (ru) 2008-12-10
NO20051296L (no) 2005-05-13
AU2003263846B2 (en) 2009-12-17
KR20050067384A (ko) 2005-07-01
JP4596913B2 (ja) 2010-12-15
US20040043960A1 (en) 2004-03-04
MXPA05001844A (es) 2005-04-19
DE60315164T2 (de) 2008-04-30
RU2005106997A (ru) 2005-11-10
ATE368048T1 (de) 2007-08-15
DE60315164D1 (de) 2007-09-06
WO2004016635A3 (en) 2004-04-08
EP1537133B1 (en) 2007-07-25
AU2003263846A1 (en) 2004-03-03
WO2004016635A2 (en) 2004-02-26

Similar Documents

Publication Publication Date Title
AU2008249143B2 (en) Partial and full agonists of A1 adenosine receptors
JP2010513565A (ja) Ａ１アデノシン受容体の部分アゴニストまたは完全アゴニストとしてのアデノシン誘導体
JP5042996B2 (ja) Ａ１アデノシンレセプターアゴニスト
US7163928B2 (en) Partial and full agonists of A1 adenosine receptors
CN100480255C (zh) A1腺苷受体的部分和完全激动剂
JP2008505967A (ja) Ａ１アデノシンレセプターアゴニストの製造方法
JP2008540685A (ja) Ａ１アデノシンレセプターアゴニスト
US20090137520A1 (en) A1 adenosine receptor agonists
HK1130805A (en) Partial and full agonists of a1 adenosine receptors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: GILEAD PALO ALTO CO., LTD.

Free format text: FORMER OWNER: CV PHARMACEUTICAL CO., LTD.

Effective date: 20100519

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20100519

Address after: American California

Patentee after: Cv Therapeutics Inc.

Address before: American California

Patentee before: CV Therapeutics Inc.

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090422

Termination date: 20110815